Company intelligence / Profile preview

Nerviano Medical Sciences

Ownership: Private
Employees: ~400
Development stage: Commercial

Overview

Developing a portfolio of oncology drugs including PARP1 inhibitor NMS-293 which shows high bone marrow tolerability in initial safety data, supporting future clinical combinations in solid tumors[7]

Therapeutic areas: Oncology
Modalities: Small MoleculesAntibody-Drug Conjugates (ADCs)
Industry: Biotech

Drug pipeline

29 assets

s 81694

28 more assets in the full pipeline.

Request access →

Partnerships

Previously partnered with Merck KGaA (reacquired rights to NMS-293 in 2024)[7]

Beyond the preview

Go deeper on Nerviano Medical Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nerviano Medical Sciences.

Explore the full profile